ATRS Key Stats
- Antares Pharma Welcomes Marvin Samson to Board of Directors Business Wire May 23
- Long-Term Biotech: 3 Names To Discover Now May 21
- 2013 FDA Drug Approval Calendar May 21
- SmithOnStocks Opines On Stocks: May 19th Edition May 19
- 3 Most Important Upcoming FDA Decisions of 2013 May 17
- Finding Value in the Medical Products and Device Spaces: An Experienced Portfoli... May 17
- Antares: Reiteration Of My Buy Recommendation May 16
- Contraceptive Ring: Another Under-The-Radar Catalyst For Antares May 15
- Earnings Volatility Drives These Healthcare Stocks in a New Direction May 12
- Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare C... May 9
ATRS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Antares Pharma is up 36.82% over the last year vs S&P 500 Total Return up 28.33%, 3SBio up 21.66%, and Endologix down 0.64%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ATRS
Pro Report PDF for ATRS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ATRS Pro Report PDF
Pro Strategies Featuring ATRS
Did Antares Pharma make it into our Pro Portfolio Strategies?